Eli Non Current Assets Total from 2010 to 2024

LLY Stock  USD 745.69  14.36  1.96%   
Eli Lilly Non Current Assets Total yearly trend continues to be fairly stable with very little volatility. Non Current Assets Total are likely to outpace its year average in 2024. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1985-12-31
Previous Quarter
34.9 B
Current Value
38.3 B
Quarterly Volatility
8.8 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.5 M, Interest Expense of 327.9 M or Total Revenue of 35.8 B, as well as many exotic indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
  
This module can also supplement Eli Lilly's financial leverage analysis and stock options assessment as well as various Eli Lilly Technical models . Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Eli Lilly and over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Eli Lilly's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Eli Non Current Assets Total Regression Statistics

Arithmetic Mean25,386,277,667
Geometric Mean22,287,037,304
Coefficient Of Variation34.65
Mean Deviation5,747,189,511
Median24,998,400,000
Standard Deviation8,795,332,049
Sample Variance77357865.9T
Range38.2B
R-Value0.87
Mean Square Error19717900.7T
R-Squared0.76
Significance0.000021
Slope1,718,260,554
Total Sum of Squares1083010122T

Eli Non Current Assets Total History

202440.2 B
202338.3 B
202231.5 B
202130.4 B
202029.2 B
201925.6 B
201823.4 B

About Eli Lilly Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Eli Lilly income statement, its balance sheet, and the statement of cash flows. Eli Lilly investors use historical funamental indicators, such as Eli Lilly's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Eli Lilly investors may use each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eli Lilly Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total38.3 B40.2 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out the analysis of Eli Lilly Correlation against competitors.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.78
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.